3.30
-0.63 (-16.03%)
前收盘价格 | 3.93 |
收盘价格 | 3.94 |
成交量 | 180,702 |
平均成交量 (3个月) | 43,858 |
市值 | 49,371,628 |
价格/销量 (P/S) | 1.15 |
股市价格/股市净资产 (P/B) | 1.72 |
52周波幅 | |
利润日期 | 4 Aug 2025 - 8 Aug 2025 |
营业毛利率 | -7.98% |
营业利益率 (TTM) | 11.03% |
稀释每股收益 (EPS TTM) | -0.240 |
季度收入增长率 (YOY) | 37.80% |
总债务/股东权益 (D/E MRQ) | 36.84% |
流动比率 (MRQ) | 1.25 |
营业现金流 (OCF TTM) | 5.42 M |
杠杆自由现金流 (LFCF TTM) | 3.56 M |
资产报酬率 (ROA TTM) | -2.70% |
股东权益报酬率 (ROE TTM) | -11.86% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
股票 | Cumberland Pharmaceuticals Inc. | - | - |
AIStockmoo 评分
分析师共识 | -2.0 |
内部交易活动 | NA |
价格波动 | 1.0 |
技术平均移动指标 | -2.5 |
技术振荡指标 | -0.5 |
平均 | -1.00 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Value |
内部持股比例 | 41.54% |
机构持股比例 | 28.76% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Berkshire Asset Management Llc/Pa | 31 Mar 2025 | 153,810 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合